Join        Login             Stock Quote

Life Sciences Fund Eyes 'Unmet Needs'

 May 11, 2012 11:19 AM

(by Brian J. Egli, S&P Capital IQ. The Outlook)

Andrew Acker, portfolio manager of the Janus Global Life Sciences Fund (JAGLX), takes as his mission finding companies that are "addressing unmet medical needs and providing efficient and cost-effective health care solutions."

Unmet medical needs, Acker explains, include such areas as cancer, Alzheimer's disease, diabetes, and cystic fibrosis, while cost-effective health care solutions involve primarily lowering health care costs.

Acker says that he and a team of five analysts "have over 75 years of combined investment experience in the health care space." Each analyst covers about 30 stocks, rating them strong buy, buy, neutral, or sell.

[Related -Bogle Says Indexing Destined To Win The Battle Of The Quants]

"We take a balanced approach with diversification across geographies, market caps, and subsectors within health care," says Acker. "By that I mean pharmaceuticals, biotechnology, health care services, and medical devices."

The fund is long-term focused, aimed at delivering consistently strong returns. "Our goal is to outperform our peers and the broader markets over an economic cycle," Acker says.

In seeking fund candidates, Acker and his team query physicians, attend medical conferences, and read scientific literature. "We believe in the power of deep fundamental research," he says. "We seek to understand the sci ence and the business."

Once a candidate is identified, it is incorporated into a detailed financial model to assess its estimated intrinsic value. A successful candidate is one that trades at a significant discount to this value.

[Related -VMAX and VMIN Poised to Be Most Important VIX ETP Launch in Years]

JAGLX typically holds 50 to 70 stocks. As of March 30, 2012, four of its top-10 holdings earned our highest 5-STARS rating by S&P Capital IQ equity analysts: Celgene (CELG), the maker of the blood cancer drug Revlimid; Express Scripts (ESRX); Valeant Pharmaceuticals (VRX); and Mylan (MYL).

"We've owned it for nine to 10 years," says Acker of Celgene. "We were investing in the company when this [Revlimid] was still in early development. And now it's one of the best-selling cancer drugs in the world, with about $3 billion in sales."

Acker acknowledges there are risks to investing in companies focused on addressing unmet medical needs.

This can be especially true for companies with a single product, given the numerous clinical trials and regulatory approvals that must be met. "At any step of the way the drug could fail," Acker says.

"We try to adjust the position of high-risk stocks in the portfolio so that in a worst-case scenario the impact on the portfolio would be less than 1%," the manager adds.

Acker has been portfolio manager of JAGLX since 2007. "What sets us apart [from peers] is the quality of our team, the depth of our research, and our commitment to generating long-term results for our investors," he says.

And Acker does eat his own cooking. "I personally have over two years of salary invested in the product," he attests.



Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageBogle Says Indexing Destined To Win The Battle Of The Quants

Vanguard founder John Bogle gave a powerful speech last month at the Q Group’s Spring Seminar that lays out read on...

article imageVMAX and VMIN Poised to Be Most Important VIX ETP Launch in Years

REX Shares is launching two new VIX exchange-traded products on Tuesday in what is likely to be the most read on...

article imageThe April 29 Gold Triangle Breakout Update

If you’re just watching stocks, you may be missing this powerful Triangle Breakout surge in read on...

article imageSell In May, But It Is A Presidential Election Year

With May just around the corner, articles covering the "Sell in May' phenomenon are not in short supply and read on...

Popular Articles

Daily Sector Scan
Partner Center

Related Articles:

The April 29 Gold Triangle Breakout Update
More Articles on: Medical

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.